Axonics, Inc. (AXNX)

NASDAQ: AXNX · IEX Real-Time Price · USD
61.01
-0.06 (-0.10%)
Feb 2, 2023, 10:32 AM EST - Market open
-0.1%
Market Cap 3.02B
Revenue (ttm) 240.92M
Net Income (ttm) -75.53M
Shares Out 49.53M
EPS (ttm) -1.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 102,415
Open 61.50
Previous Close 61.07
Day's Range 60.21 - 63.07
52-Week Range 38.41 - 79.92
Beta 0.43
Analysts Buy
Price Target 85.23 (+39.7%)
Earnings Date Feb 23, 2023

About AXNX

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and ... [Read more]

Industry Medical Devices
Sector Healthcare
CEO Raymond Cohen
Employees 517
Stock Exchange NASDAQ
Ticker Symbol AXNX
Full Company Profile

Financial Performance

In 2021, Axonics's revenue was $180.29 million, an increase of 61.64% compared to the previous year's $111.54 million. Losses were -$80.07 million, 45.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for AXNX stock is "Buy." The 12-month stock price forecast is $85.23, which is an increase of 39.70% from the latest price.

Price Target
$85.23
(39.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfun...

2 days ago - Business Wire

Axonics (AXNX) Soars 10.6%: Is Further Upside Left in the Stock?

Axonics (AXNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

3 weeks ago - Zacks Investment Research

Why Axonics Shares Are Trading Higher Today? - Axonics (NASDAQ:AXNX)

Axonics, Inc. AXNX shares are trading higher after the company reported preliminary fourth-quarter and full-year 2022 total net revenue results above estimates. The company also issued FY23 revenue gu...

3 weeks ago - Benzinga

Axonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue Guidance

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfun...

3 weeks ago - Business Wire

6 Favorite Biotech Bets For 2023

Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's...

Other symbols: AVXLMNKDNBIXSAVAVRTX
3 weeks ago - Forbes

3 Hot Stocks Going Into the Holiday Weekend

All three of these top-ranked stocks have recently gone on nice runs, giving shareholders some holiday cheer. Can the strength spill over into the new year?

Other symbols: AMRKCALM
1 month ago - Zacks Investment Research

Axonics to Present at the 41st Annual J.P. Morgan Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfun...

1 month ago - Business Wire

Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?

Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.

1 month ago - Zacks Investment Research

Axonics Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfun...

1 month ago - Business Wire

Axonics® to Participate in the Piper Sandler Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfun...

2 months ago - Business Wire

Are Medical Stocks Lagging Axonics (AXNX) This Year?

Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.

2 months ago - Zacks Investment Research

Axonics® Ranked No. 4 on the 2022 Deloitte Technology Fast 500™ List of the Fastest Growing Companies in North America

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfun...

2 months ago - Business Wire

Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Tops Revenue Estimates

Axonics (AXNX) delivered earnings and revenue surprises of 27.66% and 12.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Axonics® Reports Third Quarter 2022 Financial Results

IRVINE, Calif.

3 months ago - Business Wire

Is a Surprise Coming for Axonics (AXNX) This Earnings Season?

Axonics (AXNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

3 months ago - Zacks Investment Research

Axonics Modulation Technologies (AXNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Axonics (AXNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

3 Medical Info System Stocks to Gain on Rising Demand for Digital Health

Zacks Medical Info Systems industry stocks like Inspire Medical Systems, Inc. (INSP), Axonics (AXNX), and Pulmonx Corporation (LUNG) are expected to gain on rising demand for telehealth.

Other symbols: INSPLUNG
3 months ago - Zacks Investment Research

Axonics® to Report Third Quarter 2022 Financial Results on October 31

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

4 months ago - Business Wire

Has Axonics (AXNX) Outpaced Other Medical Stocks This Year?

Here is how Axonics Modulation Technologies (AXNX) and Molina (MOH) have performed compared to their sector so far this year.

4 months ago - Zacks Investment Research

Axonics Inc. (AXNX) Soars to 52-Week High, Time to Cash Out?

Axonics (AXNX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

5 months ago - Zacks Investment Research

Axonics® Announces First Patient Implants in Canada With New Recharge-Free Sacral Neuromodulation System

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

5 months ago - Business Wire

Axonics® to Participate in September Investor Conferences

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

6 months ago - Business Wire

Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

6 months ago - Business Wire

Here's Why Axonics Modulation Technologies (AXNX) is a Great Momentum Stock to Buy

Does Axonics Modulation Technologies (AXNX) have what it takes to be a top stock pick for momentum investors? Let's find out.

6 months ago - Zacks Investment Research

Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriter's Option to Purchase Additional Stock

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bo...

6 months ago - Business Wire